Objective:

To evaluate the predictive efficiency of the Cardiometabolic Index (CMI) for long-term adverse cerebrovascular events in patients with acute ischemic stroke (AIS) who underwent thrombolytic therapy.

Approach:

Key Findings:

• CMI showed superior predictive performance for long-term adverse cerebrovascular events compared to conventional biomarkers.
• A high CMI value (≥0.80) was independently correlated with an increased risk of MACEs.
• Systemic inflammation partially mediated the predictive effect of CMI on adverse clinical outcomes.

Interpretation:

CMI is a reliable prognostic biomarker that reflects metabolic and inflammatory status, enhancing risk stratification and treatment strategies for AIS patients post-thrombolysis.

Limitations:

• The study is retrospective and conducted at a single center.
• Further large-sample cohort studies are necessary to confirm the findings.

Conclusion:

CMI provides better predictive capability for adverse cerebrovascular events in AIS patients after thrombolytic therapy, warranting further investigation for clinical applicability.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.